FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Hasnain Faheem		 2. Issuer Name and Ticker or Trading Symbol

Gossamer Bio, Inc. [ GOSS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President & CEO
(Last)          (First)          (Middle)

3013 SCIENCE PARK ROAD		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/20/2023
(Street)

SAN DIEGO, CA 92121		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/20/2023  P  168683 A$1.0344 (1)3786008 I By family trust 
Common Stock 3/21/2023  P  269389 A$1.1965 (2)4055397 I By family trust 
Common Stock 3/22/2023  P  440500 A$1.1432 (3)4495897 I By family trust 
Common Stock         143465 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $1.21 3/20/2023  A   544500     (4)3/19/2033 Common Stock 544500.0 $0 544500 D  
Explanation of Responses:
(1) This transaction was executed in multiple trades at prices ranging from $0.97 to 1.09 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(2) This transaction was executed in multiple trades at prices ranging from $1.155 to $1.21 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(3) This transaction was executed in multiple trades at prices ranging from $1.06 to $1.20 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(4) 25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Hasnain Faheem
3013 SCIENCE PARK ROAD
SAN DIEGO, CA 92121		X
President & CEO
Signatures
/s/ Jeff Boerneke, Attorney-in-Fact3/22/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Gossamer Bio Charts.
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Gossamer Bio Charts.